making new medical technologies available in Hungary

One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE)

Corrado Tamburino1, MD, PhD; Davide Capodanno1*, MD, PhD; Andrejs Erglis2, MD; Ian B.A. Menown3, MD, FRCP; Iván G. Horváth4, MD, PhD; Raul Moreno5, MD; Timothy J. Gilbert6, MB, FRCP; James J. Crowley7, MD; Paolo Calabria8, MD; Dominic J. Allocco9, MD; Keith D. Dawkins9, MD 1. Ferrarotto...
READ MORE

Percutaneous left atrial appendage closure in patients with left atrial appendage thrombus

Felix Meincke, MD; Felix Kreidel, MD; Jasper von Wedel, MD; Ulrich Schäfer, MD; Karl-Heinz Kuck, MD; Martin W. Bergmann*, MD Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany This paper also includes accompanying supplementary data published online at:...
READ MORE

One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study

Martyn R. Thomas1*, MD, PhD; Ralf Birkemeyer2, MD; Peter Schwimmbeck3, MD, PhD; Victor Legrand4, MD, PhD; Raul Moreno5, MD; Carlo Briguori6, MD; Nikos Werner7, MD; Ezio Bramucci8, MD; Imre Ungi9, MD; Gert Richardt10, MD, PhD; Paul L. Underwood11, MD; Keith D. Dawkins11, MD 1. Guy’s and St....
READ MORE

Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study

Horst Sievert1*, MD; Joachim Schofer2, MD; John Ormiston3, MBChB; Uta C. Hoppe4, MD; Ian T. Meredith5, MD; Darren L. Walters6, MD; Michel Azizi7,8, MD; Juan Diaz-Cartelle9, MD; Meital Cohen-Mazor9,10, PhD; on behalf of the REDUCE-HTN investigators 1. CardioVascular Center Frankfurt CVC,...
READ MORE

Vessix™ – Renal Denervation System

Study Design The REDUCE-HTN Post-Market Study (PMS), including the First in Man (FIM) cohort, is a prospective, non-randomized, single arm, multicenter study evaluating the Vessix™ Renal Denervation System in patients with resistant hypertension. Enrolled patients had office-based systolic...
READ MORE

SYNERGY Stent Investigator-Sponsored Research

The SYNERGY Stent Investigator-Sponsored Research1 Program will study the SYNERGY Stent in many different patient populations that interventional cardiologists see in their everyday practice. SYNERGY Stent Clinical Trials Supporting Research of the SYNERGY Stent Top 1Boston Scientific is not...
READ MORE

Boston Scientific Receives FDA Approval for WATCHMAN™ Left Atrial Appendage Closure Device

First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation Mar 13, 2015 MARLBOROUGH, Mass., March 13, 2015 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration...
READ MORE

Boston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device

Novel Stroke Risk Reduction Option for Indicated Patients with Atrial Fibrillation Mar 24, 2015 MARLBOROUGH, Mass., March 24, 2015 /PRNewswire/ — This week, four patients in the United States received the first implants of the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left...
READ MORE

EVOLVE II Trial Represents the First Successful U.S. Pivotal Trial of a Bioabsorbable Polymer Stent .

EVOLVE II Trial Represents the First Successful U.S. Pivotal Trial of a Bioabsorbable Polymer Stent . In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific (NYSE: BSX) SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent...
READ MORE